Pheochromocytomas/Paragangliomas and two cases

References

• Kohn A, Das Chromaffine Gewebe. Ergeb Acta Ent 1902; 12. 253–348.
   Google Scholar
• Jimenez C, Cote G, Arnold A, et al. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006, 91: 2831–2858.
   Web of Science ®Google Scholar
• Erickson D, Kudva YC, Ebersold MJ et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86: 5210–16.
   PubMed Web of Science ®Google Scholar
• Lo CY, Lam KY, Wat MS, et al. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 2000; 179: 212–215.
   PubMed Web of Science ®Google Scholar
• Lenders JWM, Eisenhofer G, Mannelli M, et al. Pheochromocytoma. The Lancet 2005; 366: 665–672.
   PubMed Web of Science ®Google Scholar
• Neumann HP, Bausch B, McWinney SR, et al. Germ-line mutations in non-syndromic pheochromocytoma. N Engl J Med 2002; 346: 1459–66.
   PubMed Web of Science ®Google Scholar
• Neumann, Neumann, et al. New Engl J Med 2002; 346: 1459–66.
   PubMed Web of Science ®Google Scholar
• Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocrinol Rev 2003; 24: 539–553.
   PubMed Web of Science ®Google Scholar
• Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrinol Rev 2004; 25: 309–40.
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005; 90: 2068–75.
   PubMed Web of Science ®Google Scholar
• Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90: 2110–16.
   PubMed Web of Science ®Google Scholar
• Danska AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553–558.
   PubMed Web of Science ®Google Scholar
• Peaston RT, Weinkove C. Measurement of catecholamines and their metabolites. Ann Clin Biochem 2004; 41: 17–38.
   PubMed Web of Science ®Google Scholar
• Ilias I, Pacak K Current approaches and recommended algorrhythm for the diagnostic localisation of pheochromocytoma. J Clin Endocrinol Metab 2004; 89: 479–491.
   PubMed Web of Science ®Google Scholar
• Kaetsa G, Korbonis M, Heinz E, et al. Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localisation of advanced neuroendocrine tumours. J Clin Endocrinol Metab 2001; 86: 895–962.
   PubMed Web of Science ®Google Scholar
• Van der Hurst E, de Herder WW, Bruinig HA, et al. 123I-metaiodobenzyl-guanidine and 111 In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 96: 685–93.
   Google Scholar
• Kaetsa G, Korbonis M, Heinz E, et al. Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localisation of advanced neuroendocrine tumours. J Clin Endocrinol Metab 2001; 86: 895–962.
   PubMed Web of Science ®Google Scholar
• Adams S, Acker P, Lorenz M, et al. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma. Comparison of preoperation and intraoperative tumour localisation. Cancer 2001; 92: 263–73
   PubMed Web of Science ®Google Scholar
• Shulkin BL, Thompson NW, Shapiro B et al. Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35–41;
   PubMed Web of Science ®Google Scholar
• Hoegerle S, Nitzsche E, Altehoefer C, et al, Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 2002; 222: 507–12.
   PubMed Web of Science ®Google Scholar
• Kinney MA, Navy BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359–69.
   PubMed Web of Science ®Google Scholar
• Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragan-gliomas. Anaesthesia 2005; 60: 439–44.
   PubMed Web of Science ®Google Scholar
• Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001; 12: 469–75.
   PubMed Web of Science ®Google Scholar
• Rose B, Mathay KK, Price D, et al. Highdose 131MIBG therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98: 239–48.
   PubMed Web of Science ®Google Scholar